137  0 Kommentare Natera Announces Data from the ProActive Study that Supports Prospera Kidney as an Early Indicator of Transplant Rejection

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection in kidney transplant patients, as well as additional presentations that showcase the utility of Prospera in kidney and heart transplantation. The Company’s presence at ATC includes three oral presentations, several posters, and a symposium led by medical experts in kidney transplantation.

“We’re excited to unveil new data at ATC that reinforces dd-cfDNA as a leading indicator of transplant rejection,” said Suphamai Bunnapradist, MD, MS, professor of medicine, David Geffen School of Medicine at UCLA. “The ProActive study demonstrates that Prospera Kidney provides highly accurate and early insight into allograft health using a non-invasive tool. I’m optimistic that this study will help transform the current standard of care for patients with kidney transplants by optimizing the management of these patients to improve long-term outcomes.”

Key highlights from the ProActive Study interim analyses presented at ATC included:

• Prospera Kidney dd-cfDNA predicted ABMR up to four months, and TCMR up to two months, in advance of biopsy-proven rejection, underscoring the value of Prospera.
• 86.9% of stable kidney transplant recipients had dd-cfDNA persistently below 1%, further supporting Prospera as a reliable indicator of allograft stability.
• Patients with biopsy-proven rejection showed a 60X median elevation in dd-cfDNA% vs baseline, compared to just 1.3X median elevation in the non-rejection group, indicating that Prospera may allow for real-time prediction of rejection risk through continuous monitoring of dd-cfDNA level changes.

Lesen Sie auch

Jahresprognose gesenkt

-16 Prozent: Diesen US-Krankenversicherer zerreißen Anleger heute in der Luft

01.05.24, 19:24

Mercedes ist DAX-Spitze

Die große Dividendenstudie: Wer erhöht? Wer streicht?

01.05.24, 10:22

Ihre wichtigsten Termine

Q-Zahlen von GSK, First Solar, Qualcomm, Pfizer, Mastercard, Kraft-Heinz

01.05.24, 04:30

Quartalszahlen

Dividendenaristokrat 3M kürzt Dividende: Aktie trotzdem an der Dow-Jones-Spitze!

30.04.24, 17:09

“We’re proud to be leading such impactful studies in kidney transplantation and to be presenting findings from these studies with our esteemed partners at ATC this year,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera. “Our data presentations further support the use of the Prospera test as a reliable, non-invasive tool that outperforms other standard clinical markers. We look forward to publishing data from the ProActive study and sharing additional readouts from our studies in the future.”